From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge
The study of trimethylamine oxide (TMAO), a metabolite of gut microbiota, and heart failure and chronic kidney disease has made preliminary achievements and been summarized by many researchers, but its research in the field of cardiorenal syndrome is just beginning. TMAO is derived from the trimethy...
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Frontiers Media S.A.
2023-11-01
|
| Saila: | Frontiers in Pharmacology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1291922/full |